A provider's guide to helping patients afford thyroid meds after Adthyza's discontinuation. Covers savings programs and coupons.
As a prescriber, you already know the clinical math: patients who can't afford their medication don't take it. For thyroid patients specifically, the consequences of non-adherence are significant — worsening hypothyroid symptoms, elevated TSH, cardiovascular risk, and in pregnant patients, potential harm to fetal development.
With Adthyza discontinued as of November 2025, many of your patients who relied on this natural desiccated thyroid (NDT) medication are now navigating a confusing landscape of alternatives, insurance changes, and out-of-pocket cost shifts. This guide gives you practical tools to help them manage costs and maintain adherence.
Understanding the current cost landscape helps you recommend realistic options:
Before discontinuation, Azurity's Patient Direct program offered Adthyza at approximately $35/month (30-day) or $90/month (90-day) with home delivery, no insurance required. This program ended when the drug was discontinued. Patients who were on this program need new savings strategies for their replacement medication.
Several manufacturers offer savings programs that your patients may qualify for:
AbbVie offers patient assistance programs for qualifying patients. While Armour Thyroid's cash price is already relatively affordable at $35-$43/month, patients with financial hardship may be eligible for reduced-cost or free medication through AbbVie's patient support programs. Have your patients visit AbbVie's website or call their patient assistance line for eligibility details.
For patients switching to brand-name Levothyroxine, the Synthroid savings card can reduce copays significantly for commercially insured patients. This is worth mentioning to patients who have insurance but face high copays on brand-name medications.
IBSA Pharma offers a savings program for Tirosint (Levothyroxine gel caps) that can reduce out-of-pocket costs for eligible patients. Consider Tirosint for patients who have absorption issues with standard tablets, particularly those who take PPIs, have GI conditions, or are sensitive to inactive ingredients like lactose or gluten.
For patients paying cash or facing high copays, discount card programs can provide significant savings:
These programs are free for patients and can be used even if they have insurance (useful when their insurance copay is higher than the discount card price). Encourage your staff to keep a few of these bookmarked for quick patient counseling.
Generic Levothyroxine is available through Walmart's $4 prescription program (30-day supply) or $10 for 90 days at many Walmart pharmacy locations. For patients where synthetic T4 is clinically appropriate, this is one of the most affordable options available.
For patients who are uninsured or underinsured and truly struggling to afford their medication:
Many of these programs require a provider signature or letter of medical necessity. Having a templated letter ready for thyroid patients can streamline the process for your practice.
For patients who can't access or afford NDT medications, therapeutic substitution to synthetic Levothyroxine is the most straightforward path to cost savings:
When converting from NDT to Levothyroxine, the general guideline is:
For patients who felt better on NDT's T4+T3 combination, consider prescribing Levothyroxine + Liothyronine (Cytomel) separately. While this requires managing two prescriptions, it allows precise control over T4 and T3 doses independently. Generic Liothyronine is relatively affordable at $15-$40/month.
Proactively addressing cost can prevent the downstream problems of non-adherence. Here are practical ways to integrate cost conversations:
Train your front desk and nursing staff to proactively share savings resources. A simple handout listing GoodRx, NeedyMeds, and manufacturer programs — tailored to thyroid medications — can be given to every hypothyroid patient at checkout.
Medfinder for Providers helps you and your staff quickly check which pharmacies have specific thyroid medications in stock. This is especially valuable during the current NDT supply uncertainty. Rather than having patients call pharmacy after pharmacy, you can point them to the right location before they leave your office.
The FDA's August 2025 announcement to remove all Desiccated Thyroid Extract products from the market has created significant uncertainty for both patients and providers. Key considerations:
For a clinical perspective on the NDT shortage, read our provider-focused update: Adthyza Shortage: What Providers and Prescribers Need to Know. For guidance on helping patients locate medications, see our Provider's Guide to Helping Patients Find Adthyza in Stock.
The cost barrier to thyroid medication adherence is real and growing — especially as the NDT landscape shifts under patients' feet. By proactively addressing cost, knowing the savings programs available, and building affordability conversations into your clinical workflow, you can help your patients maintain the thyroid hormone levels they need to stay healthy.
Remember: the cheapest medication is worthless if the patient can't afford it. The best medication is the one they can access, afford, and take consistently.
Visit Medfinder for Providers for tools to help your practice support thyroid patients through this transition.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
